Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education Abstract #1525

Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Aim(s): To identify side-effects reported in clinic which would guide both patient management and teaching.
Materials and methods: A retrospective review of patients receiving Everolimus between 2011 to 2015.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P

To read results and conclusion, please login ...

Further abstracts you may be interested in

#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.
Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Maria Pia Brizzi
#1667 A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies
Introduction: Despite extensive efficacy date and limited data examining drug related side effects, the patient experience and quality of life data is limited for this patient group
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Elizabeth Quaglia
Keywords: Sunitinib, everolimus